Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
41.97
Dollar change
+0.18
Percentage change
0.43
%
IndexRUT P/E- EPS (ttm)-2.91 Insider Own2.83% Shs Outstand64.42M Perf Week2.34%
Market Cap2.70B Forward P/E- EPS next Y-3.25 Insider Trans0.00% Shs Float62.60M Perf Month-18.30%
Income-141.43M PEG- EPS next Q-0.69 Inst Own94.13% Short Float9.42% Perf Quarter3.25%
Sales6.88M P/S392.98 EPS this Y0.34% Inst Trans2.09% Short Ratio6.19 Perf Half Y53.51%
Book/sh7.68 P/B5.47 EPS next Y-11.54% ROA-34.56% Short Interest5.90M Perf Year20.67%
Cash/sh6.55 P/C6.41 EPS next 5Y- ROE-37.45% 52W Range22.11 - 53.18 Perf YTD5.82%
Dividend Est.- P/FCF- EPS past 5Y27.41% ROI-32.88% 52W High-21.08% Beta1.49
Dividend TTM- Quick Ratio13.87 Sales past 5Y30.09% Gross Margin56.30% 52W Low89.82% ATR (14)2.12
Dividend Ex-Date- Current Ratio13.87 EPS Y/Y TTM-21.42% Oper. Margin-2063.66% RSI (14)47.49 Volatility4.21% 5.35%
Employees160 Debt/Eq0.01 Sales Y/Y TTM192.02% Profit Margin-2054.76% Recom1.25 Target Price70.71
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-48.11% Payout- Rel Volume0.61 Prev Close41.79
Sales Surprise186.67% EPS Surprise-13.11% Sales Q/Q156.11% EarningsFeb 26 BMO Avg Volume952.44K Price41.97
SMA20-6.46% SMA501.91% SMA20023.52% Trades Volume579,270 Change0.43%
Date Action Analyst Rating Change Price Target Change
Dec-20-23Initiated TD Cowen Outperform
Nov-10-23Upgrade Wells Fargo Underweight → Equal Weight $27
Aug-22-23Initiated Wells Fargo Underweight $21
Sep-17-21Initiated Jefferies Buy $66
Sep-10-21Initiated SVB Leerink Outperform $68
Jul-22-21Initiated Guggenheim Buy $66
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-20-24 09:55AM
Mar-08-24 07:00AM
Mar-05-24 10:30AM
10:10AM
Feb-29-24 09:14PM
12:00PM Loading…
12:00PM
09:55AM
Feb-28-24 04:01PM
Feb-26-24 04:03PM
12:11PM
08:10AM
07:32AM
07:19AM
07:01AM
Feb-24-24 02:05PM
08:26AM Loading…
Feb-20-24 08:26AM
Feb-06-24 04:01PM
Feb-05-24 08:01AM
Nov-27-23 04:15PM
Nov-17-23 01:08PM
Nov-07-23 11:15PM
04:01PM
Nov-06-23 06:47PM
04:01PM
12:15PM
07:00AM
06:30AM
Nov-05-23 03:00PM
Nov-04-23 05:39AM
Nov-02-23 04:25PM
04:01PM Loading…
04:01PM
Sep-26-23 07:01AM
Sep-25-23 08:31AM
Aug-22-23 09:35AM
Aug-08-23 05:30PM
04:21PM
04:01PM
Jul-11-23 08:01AM
Jul-06-23 08:01AM
Jun-10-23 10:45AM
Jun-08-23 04:01PM
Jun-02-23 08:01AM
May-31-23 08:01AM
May-23-23 06:10AM
May-15-23 08:01AM
May-04-23 06:05PM
05:03PM
04:01PM
Apr-18-23 05:58AM
Apr-12-23 08:13AM
Mar-29-23 09:01AM
Mar-02-23 05:40AM
Feb-28-23 04:01PM
Feb-27-23 10:25AM
Feb-26-23 09:00AM
Feb-16-23 04:01PM
Feb-15-23 07:00AM
Feb-03-23 07:01AM
Jan-18-23 02:38PM
Dec-06-22 06:00AM
Dec-02-22 09:31AM
Nov-27-22 09:45AM
Nov-10-22 04:01PM
Nov-09-22 05:25PM
04:01PM
Nov-02-22 10:01AM
Nov-01-22 10:01AM
Aug-08-22 05:25PM
04:01PM
Jul-21-22 08:00AM
Jul-08-22 09:26AM
Jul-06-22 09:55AM
07:20AM
Jul-05-22 03:57PM
Jul-04-22 11:49AM
Jul-01-22 04:11PM
10:11AM
Jun-30-22 06:01PM
Jun-22-22 09:24AM
Jun-21-22 08:00AM
Jun-20-22 10:35AM
Jun-16-22 04:01PM
Jun-06-22 04:05PM
May-19-22 09:23AM
May-11-22 08:13AM
May-06-22 08:10AM
May-05-22 05:55PM
04:01PM
May-04-22 08:25AM
Feb-28-22 04:01PM
Feb-22-22 04:01PM
Feb-17-22 03:07AM
Feb-13-22 07:47AM
Feb-10-22 04:05PM
Feb-02-22 01:38PM
Jan-10-22 08:40AM
Dec-15-21 04:57AM
01:38AM
Dec-11-21 06:53PM
Dec-08-21 08:01AM
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jimenez Freddy A.SVP & GENERAL COUNSELFeb 13 '24Option Exercise3.8624,16693,16325,924Feb 15 04:05 PM
Martin Samuel BatesSVP AND CFOJan 02 '24Option Exercise2.7810,75029,88535,128Jan 04 04:05 PM